This double-blind, placebo-controlled, four-way balanced design crossover study included hypertensive patients aged 60-85 years with mean office-measured sitting systolic blood pressure (SBP) 160-179 mm Hg and daytime SBP X135 mm Hg. After a 2-week run-in period, during which previous medications were discontinued, each patient received the following four treatments in randomized order for 4 weeks each: lercanidipine 10 mg (L), enalapril 20 mg (E), lercanidipine 10 mg plus enalapril 20 mg (L/E) and placebo (P). At the end of each treatment period, office trough blood pressure (BP) was measured and a 24-h Ambulatory Blood Pressure Monitoring (ABPM) was performed. Seventy-five patients (mean age 66 years, office BP 168/92 mm Hg, daytime SBP 151 mm Hg) were randomized and 62 completed the study with four valid postbaseline ABPMs. The administration of P, L, E and L/E was associated with a mean 24-h SBP of 144, 137, 133 and 127 mm Hg, respectively. All active treatments significantly reduced the mean 24-h SBP in comparison with placebo, but L/E was significantly more effective than L and E alone. Similarly, office SBP was significantly more reduced with L/E (À16.9 mm Hg) than with L (À5.0 mm Hg) or E (À5.9 mm Hg). A BP o140/90 mm Hg was recorded in 18% of patients with L, 19% with E and 45% with L/E. Two patients on P and two on L/E were withdrawn from the study due to adverse events. In conclusion, combination therapy with L/E has additive antihypertensive effects on both ambulatory and office BP in elderly patients and is well tolerated.
Introduction
There is increasing evidence that the benefit associated with antihypertensive therapy is in large part due to blood pressure (BP) lowering per se, and that lowering the BP to o140/90 mm Hg is protective for the patient. The 2003 report from the Blood Pressure Lowering Treatment Trialists' Collaboration showed that when BP was reduced to o140/ 90 mm Hg, cardiovascular disease and events were also reduced. 1 On the basis of evidence from trials, the European Society of Hypertension/European Society of Cardiology joint guidelines for the management of hypertension, published in 2003, recommended that high BP be intensively lowered to at least o140/90 mm Hg and to o130/80 mm Hg in diabetics. 2 These recommendations will probably be reinforced in future guidelines, on the basis of the Valsartan Antihypertensive Long-term Use Evaluation trial, which showed that patients whose BP was controlled to o140/90 mm Hg suffered much less cardiovascular disease and fewer events than patients whose BP remained uncontrolled. 3 Recent evidence also comes from a retrospective analysis of Irbesartan Diabetic Nephropathy Trial data, in which the incidence of heart failure in high-risk hypertensive patients was lowest in patients with BP o130/90 mm Hg. 4 Unfortunately, BP control to o140/90 mm Hg is still poor in common clinical practice and it is often difficult to lower BP to o140 mm Hg, especially in the elderly. Many patients may require two or more drugs to control BP.
The importance of combination therapy is emphasized by current guidelines. In patients not adequately controlled by low-dose monotherapy, combination therapy may be a more effective option than switching to a different agent (a sometimes laborious and frustrating procedure), or increasing the dose of the original drug (with a greater probability of adverse effects). Combination therapy is also considered an alternative to monotherapy for the initial treatment of hypertension in patients with untreated high BP or who are at high risk. 2 In this study, combination therapy with a lipophilic dihydropyridine calcium antagonist with long duration of action, lercanidipine [5] [6] [7] and a well-known ACE inhibitor, enalapril, 8 was tested in hypertensive patients aged X60 years, in comparison with both drugs in monotherapy and placebo. Since elevation of systolic blood pressure (SBP) has been recognized as an independent risk factor that exceeds the risk associated with an elevated diastolic blood pressure (DBP) in older patients with hypertension, 9 SBP was chosen as the primary study variable.
Materials and methods

Study population
The study included hypertensive patients aged 60-85 years with an office sitting systolic blood pressure (SSBP) 160-179 mm Hg (inclusive), an office sitting diastolic blood pressure (SDBP) o110 mm Hg and a mean daytime SBP X135 mm Hg. To avoid administering placebo for 4 weeks to high-risk patients, patients with severe hypertension, a history of cardio-or cerebrovascular complications or diabetes mellitus requiring drug treatment were excluded from study participation. Written informed consent was obtained from all patients before their inclusion. The study was approved by the local Ethics Committees of the centres involved and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.
Study design
This was a randomized, double-blind, placebocontrolled, four-way crossover study, balanced for first-order carryover (Figure 1 ). The study was performed in two centres in Spain and two in Finland. After a 2-week run-in period, during which previous antihypertensive medications were discontinued, eligible patients were assigned a unique randomization number in chronological order of entry. Patients were randomized on the basis of this number to receive the following four treatments for 4 weeks each under blinded conditions: lercanidipine 10 mg monotherapy (L); enalapril 20 mg monotherapy (E); combination therapy with lercanidipine 10 mg plus enalapril 20 mg (L/E); and placebo (P). The duration of double-blind therapy was 16 weeks.
For each randomized patient, the investigator was provided with a set of four numbered boxes, to be dispensed one at each visit of the double-blind period. The medications were taken once daily in the morning. At the end of each treatment period, trough (2472 h post-dose) sitting BP was measured in the office and a 24-h Ambulatory Blood Pressure Monitoring (ABPM) was performed on the last day of drug intake. Drug compliance was assessed and adverse events and concomitant medications were checked at each visit. Laboratory tests, electrocardiogram and physical examination were performed at screening, at study end or in the event of early study interruption.
Run-in Double-blind, randomized period 2 weeks 4 weeks 4 weeks 4 weeks 4 weeks Standard methodology for measuring clinic BP and pulse All arterial BP measurements were taken using the same validated automatic device (Omron 705 CP) 10 in all centres. An appropriate cuff size was used to ensure accurate measurements. Two readings were taken 2 min apart after a rest of at least 10 min in a seated position. Heart rate (HR) was counted for 30 s after the second reading. If the two BP values differed by 45 mm Hg, an additional reading was taken (for a total of 3) and included into the calculated average. The patient was then asked to stand and BP and HR were measured immediately after standing up and again after 2 min in the standing position.
Standard methodology for ABPM
The same ABPM device (Spacelabs Model 90207) was supplied by Medifact Ltd, Cologne (Germany) to all centres. The ABPM studies had to be performed under similar circumstances (that is a working weekday) and patients were instructed to maintain their usual activities during the monitoring period and not engage in strenuous exercise. The ABPM device was set to obtain readings every 15 min during the day (06.00-21.59) and every 30 min during the night (22.00-05.59). All ABPMs were performed according to standardized procedures and, when the quality control criteria were not met, the ABPM had to be repeated within 7 days. The beginning of the test had to be between 0700 and 1000 hours (0630-1030 hours acceptable in exceptional circumstances), the dose intake had to occur within 5 min (up to 30 min acceptable), a minimum of 24 h was required (a minimum of 23 h acceptable in exceptional circumstances), no more than 2 non-consecutive invalid hours were accepted and 80% of data had to be valid (equivalent to 64 valid readings/24 h). A centralized reading was performed by Medifacts and the following variables were computed: mean 24 h/daytime/night-time SBP and DBP, hourly profiles and smoothness index. 11 As centres were located in both Spain and Finland, daytime and night-time values were computed both at fixed times (daytime ¼ 0600-2159 hours, night-time ¼ 2200-0559 hours) and on the basis of patient-specific 'go to bed' and 'wake up' times. The 24-h SBP was chosen as the primary efficacy parameter because the 24-h average is the most solid information provided by ABPM. 12 
Statistical analysis
Assuming that approximately 30% of the patients would not complete the study according to the protocol, 72 patients were planned for randomization (six blocks of 12 patients) in order to have at least 48 evaluable patients. The following assumptions were made: mean 24-h SBP of 150.0 and 150.6 mm Hg after the two monotherapy periods and 140.8 mm Hg after combination therapy, s.d. of 17.68, significance level of 0.05, power of 90%, correlation of within-patient measurements of 0.3. This sample size was also considered adequate to detect differences between active treatments and placebo, which was expected to show a larger effect size.
Data summarization and statistical analyses were performed using the SAS System, Version 8.02. All statistical tests were two-sided and tested at the 5% significance level. The data of the four centres participating in the study were pooled. The primary analysis was performed on the per-protocol (PP) population. We compared the change in 24-h SBP of combination therapy, lercanidipine and enalapril against placebo, using the analysis of variance for a crossover design. The differences between each of the three active treatments against placebo and an estimate of the carryover effect were assessed. Twenty-four-hour DBP, daytime/night-time and office-measured sitting SBP and DBP were analysed as for 24-h SBP, the primary efficacy variable. The statistical analyses were also performed in the ITT population (Intention To Treat, that is all patients who received at least one dose of doubleblind treatment and had at least one valid ABPM during randomized treatment). Using the same analysis of variance model as for the PP study population, an additional test was performed to compare the effect of the combination therapy against the sum of the effects of the two monotherapies.
Results
Study population
Investigators at four centres screened a total of 103 patients and 75 patients were randomized. Four patients (two on L/E and two on placebo) discontinued the study due to adverse events; three patients due to lack of efficacy (two on P and one on E), one patient on L/E due to consent withdrawn and one patient on L due to poor compliance (less than 80%). Of the 75 randomized patients, 71 received placebo, 69 lercanidipine, 70 enalapril and 72 combination therapy. The mean exposure to the different treatments was similar for each treatment group (approximately 30 days). Seventytwo patients entered in the ITT population and 62 patients completed the study according to the protocol, completing all of the four ABPMs scheduled after randomization.
Demographic and baseline characteristics for all randomized patients and for patients included in the PP and ITT analysis are shown in Table 1 . All randomized patients fulfilled ABPM selection criteria, while one patient had an SSBP o160 mm Hg (154 mm Hg). At screening, 39% of the patients had an SDBP o90 mm Hg and 24-h DBP was o85 mm Hg in 37%.
Combination therapy in elderly hypertensive patients JG Puig et al Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure; SDBP, sitting diastolic blood pressure; SSBP sitting systolic blood pressure. Note: daytime and night-time values were computed on the basis of patient specific 'go to bed' and 'wake-up' times.
Analysis of efficacy
The statistical analysis estimated the treatment effects, the period effects and the carryover effects. For all study parameters, there was a significant effect due to the treatments and no period effect. A carryover effect was observed in the PP population for 24 h/daytime and night-time SBP, but not for any other study parameters (Table 2) . However, similar results were obtained when considering least square means unadjusted and adjusted for the carryover effect. In the PP population, all active treatments significantly reduced both ambulatory and office SBP and DBP by comparison with placebo, but combination therapy was significantly more effective than enalapril or lercanidipine monotherapy ( Table 2) . For office SBP, a synergistic effect was observed in the PP population with the combination in comparison with the monotherapies: estimated difference [combinationÀ(enalapril þ lercanidipine)] ¼ À6.0, s.e. 2.91, T value À2.06, Po0.05. For 24-h SBP, no synergistic effect was observed, but as the estimated difference is not statistically significant the hypothesis of an additive effect can be supported:
Similar results were obtained in the ITT population, where no significant carryover effect was observed (data not shown).
Mean changes from placebo (least square means) observed in the PP population in the 24 h ambulatory and office SBP and DBP at trough (2472 h postdose) are shown in Figure 2 . Normalization rates (BP o140/90 mm Hg) were higher with combination therapy (45%) than with lercanidipine (18%) or enalapril (19%) monotherapies (Figure 3 ). Combination therapy improved BP control in comparison with monotherapies in the entire 24 h period, with a smoothness index for SBP of 1.3 ( Figure 4 ).
Tolerability
Nine percent of patients with placebo, 12% with lercanidipine, 16% with enalapril and 14% with the combination reported adverse events considered at least possibly related to study medication. The most common treatment-emergent adverse event was headache, which occurred more frequently with the placebo (8.5%) than with lercanidipine (2.9%), enalapril (5.7%) or combination therapy (4.2%). The adverse events causing study discontinuation in four patients were: flushing and headache (L/E), fatigue, flushing and vertigo (L/E), dizziness (P) and hypertensive crisis with eye haemorrhage (P), which was considered as serious. Another serious adverse event occurred in a patient during combination therapy (gallbladder empyema), but it was considered as non-related. No clinically significant differences in HR or in the difference between sitting and standing SBP were observed between the groups. Sitting HR at trough and 24 h HR remained stable under all treatments. 
Discussion
This study aimed to evaluate the antihypertensive efficacy of a combination therapy with lercanidipine and enalapril in comparison with the drugs in monotherapy in elderly patients with an elevated SBP, confirmed both on the basis of office BP and ABPM measurements.
In a crossover design, placebo, 10 mg lercanidipine, 20 mg enalapril and their combination were administered for 4 weeks each to every patient, in order to reduce inter-patient variability. Both office and ambulatory (24-h ABPM) measurements were performed at the end of each treatment period.
ABPM was chosen to assess the primary efficacy variable as it has several potential advantages over office BP measurement when studying the efficacy of a given antihypertensive drug, including no observer bias or digit preference, greater reproducibility, little (or no) placebo or white-coat effect and assessment under conditions of daily life for a full 24-h period between two drug administrations. 12 In addition, the 24-h average BP is more closely predictive of the incidence of cardiovascular morbidity and mortality than office-measured BP, 13 and the regression of organ damage, such as left ventricular hypertrophy, is associated more closely with treatment-induced reduction over 24 h than with office measurements. The results were consistently similar for all study parameters. All active treatments were superior to placebo, but combination therapy was significantly superior to both lercanidipine and enalapril monotherapies in reducing ambulatory (24 h/daytime/ night-time) and office SBP. Similar results were obtained for DBP, even though approximately onethird of the patients had a normal office DBP at baseline.
Normalization rates (that is, office blood pressure at trough o140/90 mm Hg) were markedly superior with the combination therapy (45%) than with each monotherapy. This is an interesting finding, as it is often acknowledged that it is difficult to lower SBP to below 140 mm Hg in the elderly. 2 To evaluate BP control over 24 h, hourly profiles were also computed, although they were only analysed descriptively as they are less reproducible than the average 24-h BP. In fact, over a short period, differences in behavioural patterns from one occasion to the other may be responsible for differences that are not due to treatment effects. 12 Even considering average hourly values, combination therapy appeared more effective than the monotherapies, with a smooth antihypertensive effect lasting the full 24 h interval between two drug administrations.
Lercanidipine was well tolerated both when administered alone 15, 16 and when given in combination with enalapril. The improved efficacy of combination therapy was therefore not associated with a worse tolerability of the treatment.
In conclusion, although BP values were significantly reduced by single-drug treatment, the reduction was significantly greater with combination therapy, both taking into consideration ABPM and office BP measurements at trough. When the two drugs were combined, additive antihypertensive effects were seen; for office SBP at trough, a synergistic effect was observed.
The results of this study may contribute to improve antihypertensive therapy for a number of reasons. First, the finding that combination therapy with enalapril and lercanidipine decreased 24-h BP by a mean of 17.9/9.2 mm Hg supports the JNC 7 recommendation to initiate therapy with two agents in patients whose BP is more than 20 mm Hg above the SBP goal or more than 10 mm Hg above the DBP goal. 17 In fact, these goals were achieved by 45% of the patients on combination therapy, and by less than 20% of the patients on monotherapy. Second, as a prompt reduction toward target BP values has been associated with a significant reduction in cardiovascular events, 18 the achievement of BP values below 140/90 mm Hg within a 4-week period may be of substantial benefit.
